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provides sustained circulatory stabilization
in patients with septic shock: a
retrospective observational before-after
study
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Abstract
Background: Direct hemoperfusion therapy with polymyxin B immobilized fiber cartridges (PMX-DHP) is widely
used for septic shock in Japan and parts of Europe. Although this treatment is usually administered for 2 h, the
optimal duration has not been established.
Methods: This retrospective study compared the effects of prolonged and conventional PMX-DHP durations (2 and
12 h, respectively) for septic shock. Between October 2013 and March 2015, 18 patients underwent conventional
PMX-DHP, and between April 2015 and May 2016, 18 patients underwent prolonged PMX-DHP. The primary
outcome was the vasopressor dependency index during the 12 h after starting the first PMX-DHP session. The
vasopressor dependency index was calculated as (inotropic score)/(mean blood pressure).
Results: The patients’ characteristics were almost similar in the conventional and prolonged PMX-DHP groups. The
major site of infection was the abdomen in both groups (61 and 72%, respectively). The conventional PMX-DHP
group had mean blood pressure values of 68.4 ± 8.9 mmHg and 78.2 ± 16.9 mmHg at 0 and 12 h after starting
PMX-DHP (P = 0.13). The prolonged PMX-DHP group had mean blood pressure values of 70.3 ± 15.7 mmHg and 87.
7 ± 16.9 mmHg at 0 and 12 h after starting PMX-DHP (P = 0.004). The conventional PMX-DHP group had
vasopressor dependency index values of 0.52 ± 0.29 and 0.39 ± 0.25 at 0 and 12 h after starting PMX-DHP (P = 0.29).
The prolonged PMX-DHP group had vasopressor dependency index values of 0.50 ± 0.26 and 0.28 ± 0.18 at 0 and
12 h after starting PMX-DHP (P = 0.01). Hospital mortality was similar in both groups (8/18 [44%] and 8/18 [44%]).
Conclusions: These findings suggest that prolonged PMX-DHP provides more sustained circulatory stabilization
compared to conventional PMX-DHP. However, our study failed to detect any improvement in mortality. Well-
designed prospective trials are needed to examine the clinical outcomes of prolonged PMX-DHP and to identify
the optimal duration of PMX-DHP.
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Background
Septic shock is the most severe form of infection and
the related mortality rate is >40% [1]. Endotoxins play a
key role in the deterioration of patients with sepsis and
can induce organ failure or shock. Endotoxemia may be
a specific therapeutic target for treating sepsis, and
patients with septic shock may undergo endotoxin
hemadsorption using direct hemoperfusion therapy with
polymyxin B immobilized fiber cartridges (PMX-DHP).
Since the early 2000s, several randomized controlled tri-
als of PMX-DHP revealed that it increased the patients’
blood pressure [2, 3] but had inconsistent effects on the
mortality rate [2–4].
The conventional duration of PMX-DHP is 2 h,
although a recent retrospective observational study
found that endotoxin removal also occurred at >2 h dur-
ing prolonged PMX-DHP [5]. Furthermore, a prospect-
ive observational study by Mitaka et al. revealed that
prolonged PMX-DHP for septic shock provided a greater
reduction of the required noradrenaline dose and
sequential organ failure assessment (SOFA) score com-
pared to conventional PMX-DHP [6]. However, no other
clinical studies have compared prolonged and conven-
tional PMX-DHP, and the clinical efficacy of prolonged
PMX-DHP is unknown. Therefore, the present study
aimed to compare prolonged and conventional PMX-
DHP among patients with septic shock, based on the
resulting blood pressure elevation, vasopressor depend-
ency index, and mortality rate.
Methods
This retrospective observational before-after study com-
pared the effects of conventional and prolonged PMX-
DHP among patients with septic shock. The study’s
design was approved by the institutional review board of
Wakayama Medical University, which waived the
requirement for informed consent because of the retro-
spective and observational nature of the study.
The patients for this study were treated in a medical-
surgical intensive care unit (ICU) at Wakayama Medical
University, which has 10 beds and a closed-ICU system.
At our institution, PMX-DHP with Toraymyxin (PMX-
20R; Toray Industries, Tokyo, Japan) is used for patients
with septic shock who require high-dose vasopressor
treatment (>0.1 μg/kg/min of noradrenaline). Between
October 2013 and March 2015, 19 patients underwent
2 h of conventional PMX-DHP (the PMX-DHP-2 h
group), and between April 2015 and May 2016, 18 pa-
tients underwent 12 h of prolonged PMX-DHP (the
PMX-DHP-12 h group). However, we excluded one pa-
tient from the PMX-DHP-2 h group who died within
24 h after the first PMX-DHP session, and only 36 pa-
tients were included in the analyses. Other management
modalities for sepsis were unchanged throughout the
study period and were based on the Surviving Sepsis
Campaign Guidelines [7] and the Japanese guidelines for
sepsis management [8].
The patients’ medical records were retrospectively
evaluated to retrieve data for the analyses. The primary
outcome was the vasopressor dependency index within
12 h after starting the first PMX-DHP session. The sec-
ondary outcomes were the mean blood pressure, the
inotropic score within 12 h after starting the first PMX-
DHP session, ICU-free days at day 28, vasopressor-free
days at day 28, renal replacement therapy (RRT)-free
days at day 28, ventilator-free days at day 28, ICU mor-
tality, hospital mortality, and the SOFA score during the
week after the first PMX-DHP session. The inotropic
score was calculated as previously described [2]: (dopa-
mine dose [μg/kg/min]) + (dobutamine dose [μg/kg/
min]) + (adrenaline dose [μg/kg/min]) × 100 + (noradren-
aline dose [μg/kg/min]) × 100 + (phenylephrine dose [μg/
kg/min]) × 100. The vasopressor dependency index was
also calculated as previously described [2]: (inotropic
score)/(mean blood pressure). The numbers of ICU-free,
vasopressor-free, RRT-free, and ventilator-free days at
day 28 were calculated by subtracting the number of
days that the patients spent in the ICU, under vasopres-
sor use, under RRT, or under ventilation after the first
PMX-DHP session. Patients who died before day 28
were assigned values of 0 for their ICU-free,
vasopressor-free, RRT-free, and ventilator-free days. The
calculations for vasopressor-free days considered dopa-
mine, adrenaline, and noradrenaline as vasopressors.
The SOFA scores were calculated for each patient
who was alive at the post-treatment time points. The
data for arterial blood gas analysis including serum
lactate levels and the PaO2/FiO2 ratio were evaluated
at 0, 2, 5, 8, and 12 h. For the collection of arterial
blood gas analysis data, the gap of actual sampling
time ±1 h was tolerated.
Statistical analysis
Continuous variables were presented as mean ± standard
deviation or median and interquartile range (IQR). Cat-
egorical variables were presented as number and per-
centage (%). The PMX-DHP-2 h and PMX-DHP-12 h
groups were compared using the Wilcoxon rank sum
test for continuous variables and Fisher’s exact test for
categorical variables. Mean blood pressures, vasopressor
dependency indexes, inotropic scores, the serum lactate,
and PaO2/FiO2 ratio were analyzed by analysis of vari-
ance following Dunnett’s test, with the reference value
being the baseline value (0 h, before starting the first
PMX-DHP session). Vasopressor dependency indexes
were compared between groups using two-way repeated
measurements analysis of variance. A two-sided P value
of <0.05 was considered statistically significant, and all
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Table 1 Patients’ characteristics
PMX-DHP-2 h (n = 18) PMX-DHP-12 h (n = 18) P value
Age, years, median [IQR] 75 (64–84) 78 (60–83) 0.75
Male, number (%) 10 (56%) 7 (39%) 0.51
Body weight, kg, median [IQR] 60 (54–65) 58 (50–64) 0.45
APACHE II score at ICU admission, median [IQR] 25 (19–31) 21 (18–30) 0.40
Comorbidity
Immunosuppression, number (%) 4 (22%) 4 (22%) 1.00
Liver cirrhosis, number (%) 2 (11%) 0 (0%) 0.49
Chronic dialysis, number (%) 0 (0%) 2 (11%) 0.49
Home oxygenation therapy, number (%) 0 (0%) 1 (6%) 1.00
Decompensate heart failure, number (%) 0 (0%) 1 (6%) 1.00
Source of admission to ICU 0.81
Operating room after emergency surgery, number (%) 9 (50%) 11 (61%)
Emergency department, number (%) 6 (33%) 5 (28%)
Hospital ward, number (%) 3 (17%) 2 (11%)
Site of infection
Abdomen, number (%) 11 (61%) 13 (72%) 0.72
Thorax, number (%) 2 (11%) 1 (6%) 0.61
Skin and soft tissue, number (%) 2 (11%) 1 (6%) 0.61
Urinary tract, number (%) 1 (6%) 2 (11%) 0.61
Others, number (%) 1 (6%) 2 (11%) 0.61
Unknown, number (%) 1 (6%) 0 (0%) 1.00
Causative microorganisms
Gram-negative rods, number (%) 4 (22%) 2 (11%) 0.66
Gram-positive cocci, number (%) 4 (22%) 3 (17%) 1.00
Gram-positive rods, number (%) 1 (6%) 0 (0%) 1.00
Fungus, number (%) 0 (0%) 1 (6%) 1.00
Mixed, number (%) 3 (17%) 7 (39%) 0.26
Unknown, number (%) 6 (33%) 5 (28%) 1.00
Number of PMX-DHP session 1.00
1 session, number (%) 6 (33%) 7 (39%)
2 sessions, number (%) 12 (67%) 11 (61%)
Start of PMX-DHP from the onset of shock or ICU admission, h, median [IQR]a 3 (2–4) 4 (3–5) 0.09
Treatment in ICU
Continuous renal replacement therapy, number (%) 11 (61%) 8 (44%) 0.51
Mechanical ventilation, number (%) 18 (100%) 18 (100%) 1.00
Low-dose steroid, number (%) 17 (94%) 15 (83%) 0.60
Dose of fluid administration within 24 h after starting PMX-DHP, ml, median [IQR] 4285 [3587–7207] 4780 [3463–8220] 0.69
Laboratory testb
White blood cell, 102/mcl, median [IQR] 77.0 (34.0–172.5) 88.2 (47.0–146.3) 1.00
C reactive protein, mg/dl, median [IQR] 13.5 (4.6–22.5) 15.9 (9.2–24.1) 0.28
Total bilirubin, mg/dl, median [IQR] 1.1 (0.8–2.1) 0.8 (0.6–1.8) 0.20
Creatinine, mg/dl, median [IQR] 1.8 (1.1–2.5) 1.6 (1.2–2.5) 0.78
PT-INR, median [IQR] 1.3 (1.2–2.0) 1.3 (1.2–1.8) 0.94
Lactate, mmol/l, median [IQR] 7.0 (4.7–11.7) 4.6 (2.0–7.6) 0.03
PMX-DHP-2 h polymyxin direct hemoperfusion for 2 h, PMX-DHP-12 h polymyxin direct hemoperfusion for 12 h, IQR interquartile range, APACHE II acute physiology
and chronic health evaluation, ICU intensive care unit, PT-INR prothrombin time-international normalized ratio
aOnset of shock was defined as the timing of inotropic score >10
bLaboratory test was performed at the day of first PMX-DHP session
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analyses were performed using JMP Pro software (ver-
sion 12.2; SAS Institute Inc., Cary, NC, USA).
Results
The patients’ characteristics are presented in Table 1.
The two groups were generally similar (no statistically
significant differences), with the exception of median
serum lactate levels being significantly higher in the
PMX-DHP-2 h group (PMX-DHP-2 h: 7.0 mmol/L
[IQR: 4.7–11.7 mmol/L]; PMX-DHP-12 h: 4.6 mmol/L
(IQR: 2.0–7.6 mmol/L); P = 0.03). The PMX-DHP-2 h
group had 18 patients (100%) with serum lactate levels
of >2 mmol/L, compared to 13 patients (72%) in the
PMX-DHP-12 h group (P = 0.046). Nine patients (50%)
in the PMX-DHP-2 h group and 11 patients (61%) in the
PMX-DHP-12 h group were admitted to the ICU from
the operating room after emergency surgery. Among
these patients, the median times from emergency de-
partment admission to operating room entrance were
1 h (IQR 1–2 h) in the PMX-DHP-2 h group and 2 h
(IQR 1–6 h) in the PMX-DHP-12 h group (P = 0.1).
The primary outcome is shown in Fig. 1 and Table 2. In
the PMX-DHP-12 h group, the vasopressor dependency
index values were significantly decreased at 8 h (P = 0.038)
and 12 h (P = 0.011). There were no significant differences
in the time courses for vasopressor dependency index
when we compared the PMX-DHP-2 h group and PMX-
DHP-12 h group (P = 0.52).
The mean blood pressure and the inotropic scores
were also shown in Table 2. In the PMX-DHP-2 h group,
the mean blood pressure value was significantly elevated
at 5 h (P = 0.01), although it was not statistically signifi-
cant at 8 h (P = 0.37) and 12 h (P = 0.13). In the PMX-
DHP-12 h group, the mean blood pressure values were
significantly elevated at 5 h (P = 0.009), 8 h (P = 0.006),
and 12 h (P = 0.004). The detailed values for each ino-
trope are shown in Additional file 1: Table S1.
The values for urinary output did not differ signifi-
cantly within 24 h after starting PMX-DHP (Additional
file 1: Table S2). The time courses of the serum lactate
and PaO2/FiO2 ratio within 12 h after starting PMX-
DHP are shown in Additional file 1: Table S3. In each
group, the statistically significant changes were not ob-
served. The SOFA scores during the week after the first
PMX-DHP session are shown in Additional file 1: Table
S4, although no significant inter-group differences were
observed at days 1, 2, 3, and 7. The other secondary
outcomes are shown in Table 3. The PMX-DHP-12 h
group had higher numbers of ICU-free, vasopressor-free,
RRT-free, and ventilator-free days, compared to the
PMX-DHP-2 h group, although these differences were not
statistically significant (ICU-free: 18 vs. 7 days, P = 0.31;
vasopressor-free: 5 vs. 21 days, P = 0.11; RRT-free: 2 vs.
20 days, P = 0.31; ventilator-free: 8 vs. 3 days, P = 0.22).
Both groups also had similar ICU mortality and hospital
mortality rates. None of the patients developed complica-
tions that were related to the PMX-DHP, including coagu-
lation in the circuit.
Discussion
The present study revealed that prolonged PMX-DHP
provided a persistent increase in blood pressure among
patients with septic shock. In contrast, patients who
received conventional PMX-DHP only experienced a
significant increase in mean blood pressure at 5 h after
starting treatment, and this significant increase was sub-
sequently lost. Similar effects were observed for the
vasopressor dependency index. Interestingly, an in vitro
study using calf serum revealed that endotoxin adsorp-
tion capacity decreased over time and reached a nadir at
approximately 2 h [9]. Thus, PMX-DHP is generally per-
formed for 2 h, according to the manufacturer’s instruc-
tion. However, a recent retrospective observational study
of 19 patients revealed that clinical endotoxin removal
was continuously observed during 24 h of prolonged
PMX-DHP [5]. Unfortunately, there are very few other
studies regarding the clinical effectiveness of prolonged
PMX-DHP. One case series of five patients with
Staphylococcus aureus toxic shock syndrome found that
prolonged PMX-DHP significantly increased systolic
blood pressure (from 89 to 125 mmHg) and decreased
the vasopressor requirement (duration 9 h, range 4–20 h)
[10]. A retrospective observational study by Yamashita
et al. also revealed that prolonged PMX-DHP (15.8 ±
7.9 h) significantly increased the mean blood pressure and
PaO2/FiO2 ratio values among patients with severe sepsis
and septic shock [11]. However, these studies are limited
by their single-arm designs and cannot conclusively
Fig. 1 Vasopressor dependency index after the first PMX-DHP
session. Multiple comparisons were performed in each group, using
Dunnett’s test, with the baseline values as the reference values (0 h;
before starting the first PMX-DHP session). PMX-DHP-2 h: polymyxin
direct hemoperfusion for 2 h, PMX-DHP-12 h: polymyxin direct
hemoperfusion for 12 h, SD: standard deviation
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demonstrate that prolonged PMX-DHP is superior to con-
ventional PMX-DHP.
Mitaka et al. performed a prospective observational
study of 16 patients with septic shock and reported that
prolonged PMX-DHP (11 patients, 16.9 ± 7.0 h) provided
a greater reduction of the required noradrenaline dose
compared to conventional PMX-DHP (five patients, 2 h)
[6]. The mean change in the noradrenaline dose (before
and after the PMX-DHP session) was –17.8 ± 14.6 μg/
min in the prolonged PMX-DHP group compared to –
1.8 ± 2.7 μg/min in the conventional PMX-DHP group
(P < 0.05). However, that study compared different time
points in the two groups, rather fixed time points, and
the interval to the outcome evaluation was longer in the
prolonged PMX-DHP group. Thus, these data are insuf-
ficient to determine whether prolonged or conventional
PMX-DHP have greater effectiveness.
The strength of the present study is its comparison of
prolonged and conventional PMX-DHP at fixed time
points, which allowed us to detect a sustained increase
in blood pressure and decrease in vasopressor depend-
ency index among the PMX-DHP-12 h group, but not in
the PMX-DHP-2 h group. Thus, prolonged PMX-DHP
may provide greater improvements in the patient’s
short-term circulatory status. Furthermore, the present
study demonstrated nonsignificant improvements in some
secondary outcomes, such as vasopressor-free days and
ventilator-free days. Sustained circulatory stabilization
might improve these clinical outcomes.
The present study also has several limitations. First,
we did not perform a randomized controlled trial, and
we cannot confirm that the groups’ patient characteris-
tics were adequately balanced. For example, serum
lactate levels were significantly higher in the PMX-DHP-
2 h group than in the PMX-DHP-12 h group, although
the similar Acute Physiology and Chronic Health Evalu-
ation II (APACHE II) scores suggested that any inter-
group differences in severity were relatively small.
Nevertheless, serum lactate levels are an important pre-
dictive factor in cases of septic shock [1], and the PMX-
DHP-2 h group may have included more severe cases.
Second, our study only evaluated the circulatory index
for a short 12-h period after starting the first PMX-DHP
session, which may explain the discrepancy between our
findings and those from previous studies that observed
increased blood pressure values at 2–3 days after con-
ventional PMX-DHP [2, 3]. Thus, it may be desirable to
evaluate mean blood pressure over a longer period, al-
though this would be difficult to interpret in our study,
because mean blood pressure would be markedly biased
by the timing of the next PMX-DHP session (which may
start at 12 h after the first session). Thus, we compared
Table 2 The time course of the vasopressor dependency index, the mean blood pressure, and inotropic score within 12 h after
starting the first PMX-DHP session
0 h (baseline) 2 h 5 h 8 h 12 h
Vasopressor dependency index, mean ± SD
PMX-DHP-2 h (n = 18) 0.52 ± 0.29 0.46 ± 0.28 0.37 ± 0.24 0.41 ± 0.28 0.39 ± 0.25
PMX-DHP-12 h (n = 18) 0.50 ± 0.26 0.43 ± 0.20 0.36 ± 0.21 0.32 ± 0.22* 0.28 ± 018*
Mean blood pressure, mmHg, mean ± SD
PMX-DHP-2 h (n = 18) 68.4 ± 8.9 76.9 ± 14.8 83.4 ± 14.2* 75.6 ± 14.9 78.2 ± 16.9
PMX-DHP-12 h (n = 18) 70.3 ± 15.7 80.7 ± 13.8 86.4 ± 15.6* 87.0 ± 18.4* 87.7 ± 16.9*
Inotropic score, mean ± SD
PMX-DHP-2 h (n = 18) 33.9 ± 17.3 33.3 ± 18.0 28.4 ± 14.8 27.4 ± 15.1 27.3 ± 15.4
PMX-DHP-12 h (n = 18) 33.8 ± 14.8 34.6 ± 15.9 29.9 ± 14.1 24.7 ± 13.8 23.1 ± 13.1
*P < 0.05 (Dunnett’s test with the reference value being the 0 h value)
Table 3 Secondary outcomes
PMX-DHP-2 h (n = 18) PMX-DHP-12 h (n = 18) P value
ICU-free days at day 28, days, median [IQR] 7 (0–23) 18 (0–24) 0.31
Vasopressor-free days at day 28, days, median [IQR] 5 [0–23] 21 [0–24] 0.11
RRT-free days at day 28, days, median [IQR] 2 [0–28] 20 [0–28] 0.31
Ventilator-free days at day 28, days, median [IQR] 3 (0–22) 18 (0–25) 0.22
ICU mortality, number (%) 7 (39%) 3 (17%) 0.26
Hospital mortality, number (%) 8 (44%) 8 (44%) 1.00
PMX-DHP-2 h polymyxin direct hemoperfusion for 2 h, PMX-DHP-12 h polymyxin direct hemoperfusion for 12 h, ICU intensive care unit, RRT renal replacement
therapy, IQR interquartile range
Miyamoto et al. Journal of Intensive Care  (2017) 5:19 Page 5 of 7
the SOFA scores over the first 7 days and there were no
significant differences in organ dysfunction and circula-
tory failure. Third, approximately 20% of our patients
had Gram-positive infections, which might decrease the
effectiveness of PMX-DHP and result in our analyses be-
ing underpowered. However, a previous study found ele-
vated endotoxin levels in cases of both Gram-negative
and Gram-positive infections [12]. In addition, PMX-
DHP has been reported to have a secondary effect of re-
moving activated monocytes and neutrophils [13]. Thus,
PMX-DHP may still provide beneficial effects in patients
with Gram-positive infections. Furthermore, the five-
patient case series found that blood pressure was in-
creased using prolonged PMX-DHP for patients with
Gram-positive infections [10]. Fourth, our study only in-
cluded a small number of patients and was underpow-
ered to detect differences in clinical outcomes, such as
mortality. Therefore, larger comparative studies are
needed to assess the true value of prolonged PMX-DHP.
Conclusions
This retrospective before-after study compared conven-
tional and prolonged PMX-DHP among patients with
septic shock and revealed that prolonged PMX-DHP
provided sustained improvements in blood pressure and
vasopressor dependency index values during the first
12 h. However, our study failed to detect any improve-
ment in mortality, which was likely related to the small
sample size. Well-designed prospective trials are needed
to examine the clinical outcomes of prolonged PMX-
DHP and to identify the optimal duration of PMX-DHP.
Additional file
Additional file 1: Table S1. The catecholamine usage and dosing
within 12 h from starting PMX-DHP. Table S2. Time course of the urine
output within 12 h after starting PMX-DHP. Table S3. Time course of the
serum lactate and PaO2/FiO2 ratio within 12 h after starting PMX-DHP.
Table S4. The SOFA score during one week after the first PMX-DHP
session. (DOCX 27 kb)
Abbreviations
APACHE II: Acute Physiology and Chronic Health Evaluation II; ICU: Intensive
care unit; IQR: Interquartile range; PMX-DHP: Direct hemoperfusion therapy
with polymyxin B immobilized fiber cartridge; PT-INR: Prothrombin time-
international normalized ratio; RRT: Renal replacement therapy; SD: Standard
deviation; SOFA: Sequential organ failure assessment
Acknowledgements
We thank Maki Kida, Yukihiro Shima, Masahiro Kaneko, Naoaki Shibata,
Atsuhiro Ogawa, Kosei Kunitatsu, Nozomu Shima, Mami Kita, Tsuyoshi
Nakashima, and Masaou Tanaka for management of the patients in our ICU.
We also thank Editage (www.editage.jp) for English language editing.
Funding
The authors received no financial support for the present study.
Availability of data and materials
The datasets supporting the conclusions of this article are included within
the article and in Additional file 1: Tables S1–S4.
Authors’ contributions
KM planned and conducted the study, collected the data, and drafted the
manuscript. YK helped to plan the study and draft the manuscript. SK helped
to draft the manuscript. All authors have read and approved the final
manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethical approval and consent to participate
This study was conducted in accordance with the principles of the
Declaration of Helsinki. This study was approved by the institutional review
board at Wakayama Medical University, which waived the requirement for
informed consent because of the observational nature of the study.
Author details
1Department of Emergency and Critical Care Medicine, Wakayama Medical
University, 811-1, Kimiidera, Wakayama City, Wakayama, Japan. 2Division of
Emergency and Critical Care Medicine, Tohoku University Hospital
Emergency Center, 1-1, Seiryo-machi, Aoba-ku, Sendai City, Miyagi, Japan.
Received: 24 November 2016 Accepted: 15 February 2017
References
1. Shankar-Hari M, Phillips GS, Levy ML, Seymour CW, Liu VX, Deutschman CS,
Angus DC, Rubenfeld GD, Singer M. Sepsis Definitions Task Force.
Developing a new definition and assessing new clinical criteria for septic
shock: for the Third International Consensus Definitions for Sepsis and
Septic Shock (Sepsis-3). JAMA. 2016;315:775–87.
2. Cruz DN, Antonelli M, Fumagalli R, Foltran F, Brienza N, Donati A, Malcangi
V, Petrini F, Volta G, Bobbio Pallavicini FM, Rottoli F, Giunta F, Ronco C. Early
use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS
randomized controlled trial. JAMA. 2009;301:2445–52.
3. Vincent JL, Laterre PF, Cohen J, Burchardi H, Bruining H, Lerma FA,
Wittebole X, De Backer D, Brett S, Marzo D, Nakamura H, John S. A pilot-
controlled study of a polymyxin B-immobilized hemoperfusion cartridge in
patients with severe sepsis secondary to intra-abdominal infection. Shock.
2005;23:400–5.
4. Payen DM, Guilhot J, Launey Y, Lukaszewicz AC, Kaaki M, Veber B, Pottecher
J, Joannes-Boyau O, Martin-Lefevre L, Jabaudon M, Mimoz O, Coudroy R,
Ferrandière M, Kipnis E, Vela C, Chevallier S, Mallat J, Robert R. ABDOMIX
Group. Early use of polymyxin B hemoperfusion in patients with septic
shock due to peritonitis: a multicenter randomized control trial. Intensive
Care Med. 2015;41:975–84.
5. Mitaka C, Fujiwara N, Yamamoto M, Toyofuku T, Haraguchi G, Tomita M.
Polymyxin B-immobilized fiber column hemoperfusion removes endotoxin
throughout a 24-hour treatment period. J Crit Care. 2014;29:728–32.
6. Mitaka C, Tsuchida N, Kawada K, Nakajima Y, Imai T, Sasaki S. A longer
duration of polymyxin B-immobilized fiber column hemoperfusion improves
pulmonary oxygenation in patients with septic shock. Shock. 2009;32:478–83.
7. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky
JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend
SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR,
Rubenfeld GD, Webb SA, Beale RJ, Vincent JL, Moreno R, Surviving Sepsis
Campaign Guidelines Committee including the Pediatric Subgroup.
Surviving sepsis campaign: international guidelines for management of
severe sepsis and septic shock: 2012. Crit Care Med. 2013;41:580–637.
8. Oda S, Aibiki M, Ikeda T, Imaizumi H, Endo S, Ochiai R, Kotani J, Shime N,
Nishida O, Noguchi T, Matsuda N, Hirasawa H. Sepsis Registry Committee of
the Japanese Society of Intensive Care Medicine. The Japanese guidelines
for the management of sepsis. J Intensive Care. 2014;2:55.
Miyamoto et al. Journal of Intensive Care  (2017) 5:19 Page 6 of 7
9. Shoji H, Tani T, Hanasaka K, Kodama M. Extracorporeal endotoxin removal
by polymyxin B immobilized fiber cartridge: designing and antiendotoxin
efficacy in the clinical application. Ther Apher. 1998;2:3–12.
10. Taniguchi T, Sato K, Kurita A, Noda T, Okajima M. Efficacy of endotoxin
adsorption therapy (polymyxin B hemoperfusion) for methicillin-resistant
Staphylococcus aureus toxic shock syndrome: a case report about five
patients. Minerva Anestesiol. 2013;79:758–61.
11. Yamashita C, Hara Y, Kuriyama N, Nakamura T, Nishida O. Clinical effects of a
longer duration of polymyxin B-immobilized fiber column direct
hemoperfusion therapy for severe sepsis and septic shock. Ther Apher Dial.
2015;19:316.
12. Marshall JC, Foster D, Vincent JL, Cook DJ, Cohen J, Dellinger RP, Opal S,
Abraham E, Brett SJ, Smith T, Mehta S, Derzko A, Romaschin A, MEDIC study.
Diagnostic and prognostic implications of endotoxemia in critical illness:
results of the MEDIC study. J Infect Dis. 2004;190:527–34.
13. Nishibori M, Takahashi HK, Katayama H, Mori S, Saito S, Iwagaki H, Tanaka N,
Morita K, Ohtsuka A. Specific removal of monocytes from peripheral blood
of septic patients by polymyxin B-immobilized filter column. Acta Med
Okayama. 2009;63:65–9.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Miyamoto et al. Journal of Intensive Care  (2017) 5:19 Page 7 of 7
